 Delayed-Action Preparations
"Delayed-Action Preparations" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Dosage forms of a drug that act over a period of time by controlled-release processes or technology.
| Descriptor ID |
D003692
|
| MeSH Number(s) |
D26.255.210 D27.720.280.210 E02.319.300.253
|
| Concept/Terms |
Controlled-Release Preparations- Controlled-Release Preparations
- Controlled Release Preparations
- Controlled-Release Preparation
- Preparation, Controlled-Release
- Preparations, Controlled-Release
|
Below are MeSH descriptors whose meaning is more general than "Delayed-Action Preparations".
Below are MeSH descriptors whose meaning is more specific than "Delayed-Action Preparations".
This graph shows the total number of publications written about "Delayed-Action Preparations" by people in UAMS Profiles by year, and whether "Delayed-Action Preparations" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2024 | 0 | 8 | 8 | | 2023 | 0 | 1 | 1 | | 2021 | 0 | 5 | 5 | | 2020 | 0 | 2 | 2 | | 2018 | 1 | 3 | 4 | | 2016 | 0 | 3 | 3 | | 2015 | 0 | 1 | 1 | | 2013 | 1 | 0 | 1 | | 2012 | 1 | 1 | 2 | | 2011 | 0 | 2 | 2 | | 2010 | 0 | 3 | 3 | | 2009 | 0 | 2 | 2 | | 2008 | 0 | 1 | 1 | | 2007 | 0 | 3 | 3 | | 2005 | 1 | 0 | 1 | | 2004 | 0 | 2 | 2 | | 2002 | 0 | 1 | 1 | | 2001 | 0 | 1 | 1 | | 1998 | 0 | 1 | 1 | | 1996 | 0 | 1 | 1 | | 1994 | 0 | 1 | 1 | | 1993 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Delayed-Action Preparations" by people in Profiles over the past ten years.
-
Yang F, Lu D, Chen Y, Qi F, Wang X, Li J, Fu Q, Li R, Wu D, Wang J, Liu D, Zhao L. Bioadhesive supramolecular polymer/hyaluronic acid hydrogel with sustained release of zinc ions and dexamethasone for diabetic wound healing. Int J Biol Macromol. 2025 Jan; 286:137752.
-
Ware OD, Stitzer ML, Umbricht A, Dunn KE. Exposure to Bupropion-SR vs. Placebo is associated with reductions in smoking among persons receiving methadone with no stated interest in smoking cessation. Addict Behav. 2025 Feb; 161:108202.
-
Hayes CJ, Raciborski RA, Nowak M, Acharya M, Nunes EV, Winhusen TJ. Medications for opioid use disorder: Predictors of early discontinuation and reduction of overdose risk in US military veterans by medication type. Addiction. 2025 Jan; 120(1):138-151.
-
Albadawi H, Zhang Z, Keum H, Cevik E, Nagalo BM, Gunduz S, Kita H, Oklu R. Percutaneous Delivery of Oncogel for Targeted Liver Tumor Ablation and Controlled Release of Therapeutics. Adv Mater. 2024 Nov; 36(45):e2406080.
-
Ranch K, Chawnani D, Jani H, Acharya D, Patel CA, Jacob S, Babu RJ, Tiwari AK, Al-Tabakha MM, Boddu SHS. An update on the latest strategies in retinal drug delivery. Expert Opin Drug Deliv. 2024 May; 21(5):695-712.
-
Saunders EC, Budney AJ, Cavazos-Rehg P, Scherer E, Bell K, John D, Marsch LA. Evaluating preferences for medication formulation and treatment model among people who use opioids non-medically: A web-based cross-sectional study. J Subst Use Addict Treat. 2024 Aug; 163:209383.
-
Desai R, Unigwe I, Riaz M, Smith SM, Shukla AM, Mohandas R, Jeon N, Park H. Comparative Safety of Long-Acting vs. Short-Acting Erythropoiesis-Stimulating Agents Among Patients Undergoing Hemodialysis. Clin Pharmacol Ther. 2024 Jul; 116(1):217-224.
-
Camacho X, Schaffer AL, Brett J, Pratt N, Buckley NA, Henry D, Pearson SA. Quality use of publicly subsidised tapentadol in Australia: a population-based analysis. Intern Med J. 2024 Jun; 54(6):941-950.
-
Espay AJ, Hauser RA, Dhall R, Thakkar S, Cloud L, Zeitlin L, Banisadr G, Fisher S, Visser H. Safety and Efficacy of IPX203 in Parkinson's Disease: The RISE-PD Open-Label Extension Study. Mov Disord. 2024 Feb; 39(2):428-432.
-
Weiss MD, Surman C, Khullar A, Owens J, He E, Cataldo M, Donnelly G. Effect of a Multilayer, Extended-Release Methylphenidate Formulation (PRC-063) on Sleep in Adolescents with Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Fixed-Dose, Placebo-Controlled Trial Followed by a 6-Month Open-Label Follow-Up. J Child Adolesc Psychopharmacol. 2021 11; 31(9):623-630.
-
Weiss MD, Cutler AJ, Kollins SH, Donnelly GAE. Efficacy and Safety of a Long-Acting Multilayer-Release Methylphenidate Formulation (PRC-063) in the Treatment of Adolescent Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind Clinical Trial with a 6-Month Open-Label Extension. J Child Adolesc Psychopharmacol. 2021 11; 31(9):610-622.
-
Weiss MD, Surman C, Khullar A, He E, Cataldo M, Donnelly G. Effect of a Multi-Layer, Extended-Release Methylphenidate Formulation (PRC-063) on Sleep in Adults with ADHD: A Randomized, Double-Blind, Forced-Dose, Placebo-Controlled Trial Followed by a 6-month Open-Label Extension. CNS Drugs. 2021 06; 35(6):667-679.
-
Woody GE, Poole S, Yu E, Carroll J, Lynch KG. Extended release injectable naltrexone before vs. after release: A randomized trial of opioid addicted persons who are in prison. J Subst Abuse Treat. 2021 08; 127:108355.
-
Annaji M, Poudel I, Boddu SHS, Arnold RD, Tiwari AK, Babu RJ. Resveratrol-loaded nanomedicines for cancer applications. Cancer Rep (Hoboken). 2021 06; 4(3):e1353.
-
Mitchell MM, Schwartz RP, Choo TH, Pavlicova M, O'Grady KE, Gryczynski J, Stitzer ML, Nunes EV, Rotrosen J. An alternative analysis of illicit opioid use during treatment in a randomized trial of extended-release naltrexone versus buprenorphine-naloxone: A per-protocol and completers analysis. Drug Alcohol Depend. 2021 02 01; 219:108422.
-
Weiss MD, Childress AC, Donnelly GAE. Efficacy and Safety of PRC-063, Extended-Release Multilayer Methylphenidate in Adults with ADHD Including 6-Month Open-Label Extension. J Atten Disord. 2021 08; 25(10):1417-1428.
-
Weiss M, Childress A, Mattingly G, Nordbrock E, Kupper RJ, Adjei AL. Relationship Between Symptomatic and Functional Improvement and Remission in a Treatment Response to Stimulant Trial. J Child Adolesc Psychopharmacol. 2018 10; 28(8):521-529.
-
Varanoske AN, Hoffman JR, Church DD, Coker NA, Baker KM, Dodd SJ, Harris RC, Oliveira LP, Dawson VL, Wang R, Fukuda DH, Stout JR. Comparison of sustained-release and rapid-release ?-alanine formulations on changes in skeletal muscle carnosine and histidine content and isometric performance following a muscle-damaging protocol. Amino Acids. 2019 Jan; 51(1):49-60.
-
Brinkley-Rubinstein L, Zaller N, Martino S, Cloud DH, McCauley E, Heise A, Seal D. Criminal justice continuum for opioid users at risk of overdose. Addict Behav. 2018 11; 86:104-110.
-
Gomes T, Jain S, Paterson JM, Sketris I, Caetano P, Henry D. Trends and uptake of new formulations of controlled-release oxycodone in Canada. Pharmacoepidemiol Drug Saf. 2018 05; 27(5):520-525.
-
Dhall R, Kreitzman DL. Advances in levodopa therapy for Parkinson disease: Review of RYTARY (carbidopa and levodopa) clinical efficacy and safety. Neurology. 2016 Apr 05; 86(14 Suppl 1):S13-24.
-
An T, Choi J, Kim A, Lee JH, Nam Y, Park J, Sun Bk, Suh H, Kim CJ, Hwang SJ. Sustained release of risperidone from biodegradable microspheres prepared by in-situ suspension-evaporation process. Int J Pharm. 2016 Apr 30; 503(1-2):8-15.
-
Jennings JA, Beenken KE, Parker AC, Smith JK, Courtney HS, Smeltzer MS, Haggard WO. Polymicrobial Biofilm Inhibition Effects of Acetate-Buffered Chitosan Sponge Delivery Device. Macromol Biosci. 2016 Apr; 16(4):591-8.
-
Stein MA, Sikirica V, Weiss MD, Robertson B, Lyne A, Newcorn JH. Does Guanfacine Extended Release Impact Functional Impairment in Children with Attention-Deficit/Hyperactivity Disorder? Results from a Randomized Controlled Trial. CNS Drugs. 2015 Nov; 29(11):953-62.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|